Carole J R Bataille
Overview
Explore the profile of Carole J R Bataille including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cogswell T, Josa-Cullere L, Zimmer D, Galan S, Jay-Smith M, Harris K, et al.
RSC Med Chem
. 2024 Sep;
PMID: 39220761
The development of a safe, efficacious, and widely effective differentiation therapy for AML would dramatically improve the outlook for many patients worldwide. To this aim, our laboratory has discovered a...
2.
Wang P, Raja A, Luscombe V, Bataille C, Lucy D, Rogga V, et al.
J Med Chem
. 2023 Dec;
67(1):110-137.
PMID: 38146625
Orphan G-protein-coupled receptor 84 (GPR84) is a receptor that has been linked to cancer, inflammatory, and fibrotic diseases. We have reported DL-175 as a biased agonist at GPR84 which showed...
3.
Brimblecombe K, Connor-Robson N, Bataille C, Roberts B, Gracie C, OConnor B, et al.
Eur J Neurosci
. 2023 Nov;
59(6):1242-1259.
PMID: 37941514
Ca entry into nigrostriatal dopamine (DA) neurons and axons via L-type voltage-gated Ca channels (LTCCs) contributes, respectively, to pacemaker activity and DA release and has long been thought to contribute...
4.
Luscombe V, Baena-Lopez L, Bataille C, Russell A, Greaves D
Eur J Pharmacol
. 2023 Aug;
956:175960.
PMID: 37543157
GPR84 is an orphan G-protein coupled receptor (GPCR) linked to inflammation. Strategies targeting GPR84 to prevent excessive inflammation in disease are hampered by a lack of understanding of its precise...
5.
Josa-Cullere L, Galan S, Cogswell T, Jackson T, Jay-Smith M, Mola L, et al.
Eur J Med Chem
. 2023 Jun;
258:115509.
PMID: 37343464
Acute myeloid leukaemia (AML) is an aggressive type of leukaemia with low rates of long-term survival. While the current standard of care is based on cytotoxic chemotherapy, a promising emerging...
6.
Jain A, Bataille C, Milhas S, Miller A, Zhang J, Rabbitts T
ACS Appl Bio Mater
. 2022 Jan;
3(12):8481-8495.
PMID: 35019618
Macromolecules such as antibodies and antibody fragments have been reported to interfere with intracellular targets, but their use is limited to delivery systems where expression is achieved from vectors such...
7.
Josa-Cullere L, Cogswell T, Georgiou I, Jay-Smith M, Jackson T, Bataille C, et al.
Molecules
. 2021 Nov;
26(21).
PMID: 34771052
Acute myeloid leukemia (AML) is the most aggressive type of blood cancer, and there is a continued need for new treatments that are well tolerated and improve long-term survival rates...
8.
Bery N, Bataille C, Russell A, Hayes A, Raynaud F, Milhas S, et al.
Sci Adv
. 2021 Apr;
7(15).
PMID: 33837087
Intracellular antibodies are tools that can be used directly for target validation by interfering with properties like protein-protein interactions. An alternative use of intracellular antibodies in drug discovery is developing...
9.
Partridge F, Bataille C, Forman R, Marriott A, Forde-Thomas J, Haberli C, et al.
ACS Infect Dis
. 2021 Apr;
7(5):1260-1274.
PMID: 33797218
Nine hundred million people are infected with the soil-transmitted helminths (roundworm), hookworm, and (whipworm). However, low single-dose cure rates of the benzimidazole drugs, the mainstay of preventative chemotherapy for whipworm,...
10.
Bataille C, Rabbitts T, Claridge T
Bio Protoc
. 2021 Mar;
10(13):e3666.
PMID: 33659336
In drug development programmes, multiple assays are needed for the determination of protein-compound interactions and evaluation of potential use in assays with protein-protein interactions. In this protocol we describe the...